Fibroblast growth factor 21 (FGF21) is a hormone-like protein primarily secreted by the liver, adipose tissue, and pancreas. It plays a key role in regulating glucose homeostasis, lipid metabolism, and energy balance by activating FGF receptors in complex with β-Klotho co-receptors. Due to its metabolic effects, FGF21 has emerged as a therapeutic target for obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).
FGF21 antibodies are tools designed to detect, quantify, or modulate FGF21 activity. In research, they are widely used in immunoassays (e.g., ELISA, Western blot) to study FGF21 expression patterns, signaling mechanisms, and interactions with metabolic pathways. Neutralizing antibodies help investigate FGF21's physiological roles by blocking its receptor binding. Conversely, agonist antibodies mimicking FGF21’s action are explored as potential therapeutics to enhance insulin sensitivity or promote weight loss.
Recent studies also highlight FGF21’s role as a stress-responsive hormone, linking metabolic adaptation to nutrient deprivation or mitochondrial dysfunction. Antibodies targeting FGF21 are critical in validating its biomarker potential for metabolic disorders. However, challenges remain, including antibody specificity across species (human, mouse) and avoiding interference with endogenous FGF21-receptor dynamics. Pharmaceutical development focuses on engineering antibodies with prolonged half-life or tissue-specific targeting to optimize therapeutic efficacy while minimizing off-target effects.